Beta thalassemia affects hemoglobin production. Blood tests, genetic findings and clinical assessment explain different parts of the condition—and no single label predicts every outcome.
Learn to interpret gene therapy trial results: response rates, endpoints, confidence intervals, safety and durability—with diagrams, real trials and a checklist.
TSC1 and TSC2 connect growth regulation with a highly variable disorder. Research interpretation requires clear diagnostic criteria, age-aware phenotyping and outcomes that reflect more than tumor size.
Gitelman syndrome connects impaired kidney salt transport with variable symptoms. Researchers must distinguish molecular mechanisms, inheritance evidence and individual clinical outcomes.
Persistent hematuria can be a clue to inherited collagen IV disease. The gene, inheritance pattern and clinical findings determine what an Alport syndrome result means.
Multiple endocrine neoplasia type 1 can connect apparently separate endocrine findings. Clinical assessment, genetic testing and continuing surveillance each answer different questions.
The language of DNA, genes, chromosomes and inheritance.
Understand genetic tests, their possibilities and their limits.
Explore methods, emerging technologies and the evidence behind discovery.
Pregnancy, childhood, inherited conditions and the diagnostic journey.
Inherited predisposition, tumour testing and the questions that connect them.
Phenotypes, variants and genomic analysis for health professionals.
News and studies from original sources. Follow the headline for the full context.
Testing relatives for a known pathogenic variant can clarify inherited risk. The original report, family context and follow-up plan determine how useful the result becomes.
Discuss scope, choice and follow-up before sequencing uncovers a medically actionable result unrelated to the original question.
A test can accurately detect the changes it was designed to find while missing others. Scope, coverage and sample choice help explain what a negative result means.
Learn to interpret gene therapy trial results: response rates, endpoints, confidence intervals, safety and durability—with diagrams, real trials and a checklist.
A high percentile is not an absolute risk, and strong association does not establish that using a score improves care.
Longer molecules can clarify structural variation and difficult regions, but analytical validation and study design still determine diagnostic value.
Multiple endocrine neoplasia type 1 can connect apparently separate endocrine findings. Clinical assessment, genetic testing and continuing surveillance each answer different questions.
DICER1 links RNA processing to a distinctive tumor spectrum. For researchers, meaningful risk estimates depend on age, recruitment and whether an outcome includes benign growths.
An October 2026 NCI retrospective revisits RAS drug discovery. The foundational KRAS G12C study shows why molecular selectivity and clinical benefit require different evidence.
Beta thalassemia affects hemoglobin production. Blood tests, genetic findings and clinical assessment explain different parts of the condition—and no single label predicts every outcome.
Persistent hematuria can be a clue to inherited collagen IV disease. The gene, inheritance pattern and clinical findings determine what an Alport syndrome result means.
Ataxia-telangiectasia affects movement, immunity and cancer risk. Understanding whether one or both ATM gene copies are affected is essential to interpreting a genetic result.
Start with a question. Explore a topic. Follow the evidence.
Find your next read →
